Overview: NGS Retinoblastoma Sequencing TestIntroduction: The NGS Retinoblastoma Sequencing Test sequences genes to diagnose retinoblastoma, causing vision issues or eye tumors. Aligned with 2023 ASCO guidelines, it uses PCR for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected retinoblastoma.
Other Names: Retinoblastoma Assay, RB1 Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Retinoblastoma sequencing began in the 1980s with tumor suppressor gene research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose retinoblastoma, guides treatment, and evaluates patients with vision issues or eye tumors.
Test Parameters: 1. Retinoblastoma Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of vision issues, eye tumors, or retinoblastoma symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document vision issues, leukocoria, eye tumors, or family history of retinoblastoma. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, retinoblastoma implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze retinoblastoma genes (e.g., RB1). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for retinoblastoma diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm retinoblastoma, guiding enucleation, chemotherapy, or genetic counseling. Negative results may require tumor biopsy.
Specialist Consultation: Consult an oncologist or ophthalmologist for result interpretation and treatment planning.
Additional Supporting Tests: Eye exam, retinal imaging, or tumor biopsy to confirm retinoblastoma diagnosis.
Test Limitations: Not all retinoblastoma cases are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: ASCO Retinoblastoma Guidelines, 2023; Journal of Clinical Oncology, Shields CL, 2022.
